Study evaluates whether Amplifi therapy enables AVF maturation at two weeks, potentially reducing catheter dependence and transforming the dialysis access pathway BOSTON, May 19, 2026 /PRNewswire/ -- ...

CRESSKILL, NJ / ACCESSWIRE / August 5, 2024 / Vascular Therapies, a biotechnology company focused on improving vascular access outcomes in patients with kidney disease, today announced completion of ...

An investigational product called Acellular Tissue Engineered Vessel demonstrated superior hemodialysis vascular access outcomes compared with AVFs in a phase 3 trial. A bioengineered human tissue ...

Arteriovenous fistula (AVF) creation is associated with a slowing of kidney function decline in patients with chronic kidney disease (CKD), new study findings suggest. Investigators retrospectively ...

This requires durable access to a blood vessel site where the dialysis machine can remove and return blood. Such access is created when a surgeon attaches a vein to an artery in the patient. The ...

TEMPE, Ariz.--(BUSINESS WIRE)--Tempe-based interventional nephrologists Randy Cooper, MD and Umar Waheed, MD, and their team at SKI Vascular Center, this week became the first ambulatory surgical ...

Amplifi Vascular Announces Major Clinical Milestone by Launching the AMPLIFI-1 Pivotal Trial to Expand Forearm Fistula Options for Hemodialysis Patients Amplifi Vascular Announces Major Clinical ...